Qiagen's Q1 Revenues up 18 Percent on Organic Growth and Asian Demand | GenomeWeb
NEW YORK (GenomeWeb News) - Qiagen yesterday said first-quarter revenue rose 18 percent as R&D spending increased 13 percent and net income was up 13 percent.
 
Total receipts for the three months ended March 31, 2007, rose to $127.9 million from $108.7 million year over year.
 
Qiagen said that the strong sales were fuelled in part by an 11 percent increase in organic growth and a 2 percent contribution from acquisitions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.